Linagliptin-Induced Bullous Pemphigoid: A Case Report and Comprehensive Literature Review
Abstract
Bullous pemphigoid (BP) is an autoimmune blistering disorder predominantly affecting the elderly, presenting significant management challenges, especially in patients with multimorbidity and polypharmacy. This report details a complex case of a 94-year-old woman with new-onset BP following dipeptidyl peptidase-4 (DPP-4) inhibitor (linagliptin) initiation, complicated by diabetes mellitus, chronic kidney disease, hypertension, and dementia. We describe her clinical course, therapeutic challenges, and response to systemic corticosteroids combined with topical therapies. Furthermore, we comprehensively review the current evidence for emerging biological and targeted therapies (e.g., rituximab, dupilumab, omalizumab, and intravenous immunoglobulin) in BP management, highlighting their potential role in reducing corticosteroid dependence and improving outcomes in frail, comorbid patients. This case underscores the importance of the prompt recognition of drug-induced BP, individualized treatment plans considering comorbidities, and the growing promise of novel therapeutic strategies.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.